Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
DWTX
DWTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DWTX News
Dogwood Therapeutics Achieves Milestone in HALT-CINP Trial
Feb 02 2026
Newsfilter
Dogwood Therapeutics Raises $12.5 Million to Advance Halneuron® Development
Jan 12 2026
Globenewswire
Dogwood Therapeutics Reports Positive Interim Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
Dec 23 2025
NASDAQ.COM
Dogwood Therapeutics (DWTX) Releases Interim Analysis of Halneuron Phase 2b Study
Dec 22 2025
Yahoo Finance
Dogwood Therapeutics Reports Positive Interim Results for Halneuron®; Top-Line Data Expected Q3 2026
Dec 22 2025
Globenewswire
Dogwood Therapeutics Registers 100 Participants in Halneuron Study for Chemotherapy-Induced Pain
Nov 11 2025
Yahoo Finance
Dogwood Therapeutics Obtains Exclusive Global, Royalty-Free License for SP16 Development and Commercialization as a Cancer Pain Treatment in All-Stock Deal Highlighting Commitment to Enhancing Cancer Patient Care
Sep 29 2025
Newsfilter
Dogwood Obtains License to Develop Serpin Pharma's SP16 IV Formulation
Sep 29 2025
NASDAQ.COM
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Aug 07 2025
Newsfilter
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Jun 03 2025
Newsfilter
HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target
Apr 23 2025
Benzinga
Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings
Apr 21 2025
Benzinga
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
Apr 11 2025
Newsfilter
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar 31 2025
Newsfilter
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Mar 18 2025
Newsfilter
Maxim Group Remains a Buy on Dogwood Therapeutics (DWTX)
Mar 13 2025
Business Insider
Show More News
